KURA News and Press, Kura Oncology Inc. From 05/04/20

Kura Oncology, Inc. (KURA) Q1 2020 Earnings Conference Call May 04, 2020 4:30 PM ET Company Participants Pete De Spain - Vice President of Investor Relations Troy Wilson - President & Chief Executive Officer Marc Grasso - Chief Financial Officer & Chief Business Officer ...

SAN DIEGO, April 29, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that it will report first quarter 2020 financial results after the clos...

Shares of Kura Oncology (NASDAQ: KURA) -- a clinical-stage biopharmaceutical company that focuses on developing cancer treatments -- were up by 42.6% as of 1:49 p.m. EDT on Tuesday. The company did not report any news, but its stock is probably riding the wave of Syndax Pharmaceuticals (...

Gainers: Creative Realities (NASDAQ: CREX ) +125% . More news on: Creative Realities, Inc., Syndax Pharmaceuticals, Inc., Kura Oncology, Inc., Stocks on the move, , Read more ...

The following slide deck was published by Kura Oncology, Inc. in conjunction with this Read more ...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

Image source: The Motley Fool. Kura Oncology, Inc.   (NASDAQ: KURA) Q4 2019 Earnings Call Feb 25, 2020 , 4:30 p.m. ET Operator Continue reading

Kura Oncology, Inc. (KURA) Q4 2019 Earnings Conference Call February 25, 2020 4:30 p.m. ET Company Participants Pete De Spain - VP, IR Troy Wilson - President and CEO Marc Grasso - CFO and Chief Business Officer Bridget Martell - Acting Chief Medical Officer Conference Call ...

– Registration-directed trial of tipifarnib in HRAS mutant head and neck squamous cell carcinomas anticipated to complete enrollment in first quarter of 2021 – – Company preparing to initiate a registration-directed trial of tipifarnib in T-cell lymphomas following po...

SAN DIEGO, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is...